The Cardiovascular Research Foundation (CRF) will release results of its landmark research study, HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) at the nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.
Merck & Co., Inc., announced that the U.S. Food and Drug Administration (FDA) granted ISENTRESS TM (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
At the request of the U.S. Food and Drug Administration (FDA), U.S. Marshals seized on Tuesday approximately $71,000 of goods from FulLife Natural Options, Inc., of Boca Raton, Fla., which marketed and distributed Charantea Ampalaya Capsules and Charantea Ampalaya Tea.
Nonprescription Drug Manufacturers Association of Canada – NDMAC and its member companies are committed to working with Health Canada toward to ensure the safety and efficacy of cough and cold medicines for children. NDMAC understands that Canadian parents may be concerned about how they should proceed when their children suffer from the symptoms of coughs and colds.
The enzyme TPPII may contribute to obesity by stimulating the formation of fat cells, suggests a study in EMBO reports this week. The enzyme, TPPII, has previously been linked to making people feel hungry, but Jonathan Graff and colleagues now show that it may be even more deeply involved in causing obesity.
An intravenous “blood thinner” widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.
Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study sponsored by NIST.
Through the generous philanthropic support of the Littlefield 2000 Trust, the American Association for Cancer Research is pleased to announce four recipients of the 2007 Jeannik M. Littlefield-AACR Grants for Metastatic Colon Cancer Research, totaling $2.7 million. Now in its second year, this competitive grant program supports the cutting-edge research of top scientists from around the world, working to accelerate the discovery and development of new treatments for metastatic colon cancer.
A tumor-blocking protein previously implicated in prostate and breast cancer development may also be behind the most aggressive type of pancreatic cancer. Researchers have discovered that the protein pp32 — which normally applies the brakes on a cancer-causing gene — is missing in an aggressive form of pancreatic cancer. Though the work is preliminary, the scientists say, the absent protein could eventually become a marker for the disease and a potential drug target.
MIT researchers have discovered a link between a gene believed to promote long lifespan and a pathway that flushes cholesterol from the body. The finding could help researchers create drugs that lower the risk of diseases associated with high cholesterol, including atherosclerosis (clogged arteries) and Alzheimer’s disease.